About Vaxart


Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on our innovative delivery platform.

We have proprietary technology, partnerships to accelerate our development, and an experienced team with deep industry expertise.

Our Mission


From the beginning, Vaxart has been on a mission to transform global health by pioneering oral pill vaccines that provide both mucosal and systemic immunity against common viral diseases.

We are dedicated to advancing vaccine science to create safe, effective, and accessible solutions that protect communities worldwide and empower people to lead healthier lives.

Our Science


Vaxart’s oral pill vaccines are designed to generate durable mucosal and systemic immunity, offering a potentially revolutionary advance in immunization technology.

VAXART News


  • Vaxart, Inc. Stockholder Fireside Chat

    Vaxart, Inc. Stockholder Fireside Chat

    Read More

  • Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results

    Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results

    Read More

  • Vaxart CEO Issues Letter to Stockholders

    Vaxart CEO Issues Letter to Stockholders

    Read More